Clinuvel Pharmaceuticals (ASX:CUV) strategic update fails to boost investor appetite

12AprApril 12, 2021

Clinuvel Pharmaceuticals (ASX:CUV) strategic update fails to boost investor appetite

Genetic and vascular disorder treatment company Clinuvel Pharmaceuticals (ASX:CUV) released a new strategic update on Monday.

The firm plans to expand its research capabilities for skin cancer treatments and damage remediation. The establishment of a new manufacturing division is on the company’s strategic agenda to advance new treatment formulas.

The strategic update has done little to boost investor appetite, as shares in Clinuvel Pharmaceuticals are trading 2.42 per cent lower at $29.39 .
Copyright 2021 – Finance News Network

Source: Finance News Network

07AprApril 7, 2021

Imugene (ASX:IMU) to proceed to final dose cohort for lung cancer treatment

07 Apr 2021 - $620 million cancer treatment provider Imugene (ASX:IMU) has announced that an independent team of researchers have certified that lung cancer drug PD1-Vaxx is safe for human use at 50 micrograms.

10AugAugust 10, 2023

Stocks of the Hour: MPower Group, True North Copper, Latin Resources

10 Aug 2023 - A snapshot of the stocks on the move, featuring MPower Group (ASX:MPR), True North Copper (ASX:TNC) and Latin Resources (ASX:LRS).

22SepSeptember 22, 2021

Stocks of the Hour: EBOS, Westpac & Zip Co

22 Sep 2021 - A snapshot of the stocks on the move, featuring EBOS (ASX:EBO), Westpac (ASX:WBC) & Zip Co (ASX:Z1P).

04FebFebruary 4, 2020

Temple & Webster’s (ASX:TPW) revenue up 50%

04 Feb 2020 - E-commerce Homewares retailer Temple and Webster (ASX:TPW) reported first-half revenue of $74.1 million, a 50 per cent increase on the year earlier period.

16JunJune 16, 2020

BetMakers Technology Group (ASX:BET) set to raise $35m to help expand into the US

16 Jun 2020 - BetMakers Technology Group (ASX:BET) is pleased to announce that it has received firm commitments to raise $35 million, before costs, by way of a placement to sophisticated and institutional investors at an offer price of $0.37 per new fully paid ordinary share.